头颈癌放疗相关淋巴水肿的系统综述与荟萃分析
该系统综述纳入26项研究共3133例接受放疗的黏膜头颈癌成人患者,采用随机效应模型合并淋巴水肿患病率。汇总患病率为49%(95%CI 36%-62%),异质性高(I2=94%);临床显著(≥2级)淋巴水肿为32%(14%-59%)。证据确定性极低。
要点
- 头颈癌放疗后淋巴水肿汇总患病率约49%,临床显著者为32%。
- 外部与内部淋巴水肿患病率分别为37%和45%。
- 证据确定性极低,淋巴水肿定义与评估方法不一。
核心结论
- 淋巴水肿影响近半数头颈癌放疗后患者,支持将常规监测、早期识别与及时转诊纳入生存期照护路径。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Embase、Scopus和Cochrane Library(2000-2025年)。
- 纳入队列、病例系列、横断面和临床试验研究,共26项研究、3133例患者。
- 采用DerSimonian-Laird随机效应模型合并经logit转换的患病率,并行Hartung-Knapp-Sidik-Jonkman方差校正。
- 本综述未前瞻性注册。
主要发现
- 淋巴水肿汇总患病率为49%(95%CI 36%-62%),异质性显著(I2=94%)。
- 外部淋巴水肿汇总患病率为37%(12%-71%),内部淋巴水肿为45%(31%-60%)。
- 报告严重程度分级的研究中,临床显著(≥2级)淋巴水肿汇总患病率为32%(14%-59%)。
- 漏斗图检查和Egger检验提示小样本效应(p=0.06)。
关键数值与推荐
- 淋巴水肿定义与评估方法在各研究间存在差异,最常用临床分级。
- 方法学质量参差不齐,证据以回顾性、单臂研究为主。
- 总体证据确定性极低。
临床怎么用
- 建议在头颈癌放疗后生存期照护中开展淋巴水肿常规监测、早期识别和及时转诊管理。
- 未来前瞻性研究应采用标准化定义和结局指标以完善风险估计并指导预防策略。
局限性
- 纳入研究以回顾性、单臂设计为主,方法学质量参差不齐。
- 淋巴水肿定义和评估方法不一致,异质性高(I2=94%)。
- 总体证据确定性极低。
- 存在小样本效应提示(Egger检验p=0.06)。
- 本综述未前瞻性注册。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the pooled prevalence of lymphedema among adults with mucosal head and neck cancer treated with radiation therapy. DATA SOURCES: PubMed, Embase, Scopus, and Cochrane Library. REVIEW METHODS: A comprehensive literature search of PubMed, Embase, Scopus, and Cochrane Library (2000-2025) identified cohort, case series, cross-sectional, and clinical trial studies reporting lymphedema after radiotherapy for head and neck cancer. Logit-transformed lymphedema prevalence was pooled using a DerSimonian-Laird random-effects model with Hartung-Knapp-Sidik-Jonkman variance correction; statistical heterogeneity was evaluated using I2. This review was not prospectively registered. RESULTS: A total of 26 studies (n = 3133 patients) met inclusion criteria. The pooled prevalence of lymphedema was 49% (95% CI, 36%-62%), with considerable heterogeneity (I2 = 94%). Subgroup analyses yielded a pooled prevalence of 37% (12%-71%) for external and 45% (31%-60%) for internal lymphedema. Among studies reporting severity-graded data, the pooled prevalence of clinically significant (grade ≥ 2) lymphedema was 32% (14%-59%). Lymphedema definitions and assessment methods varied across the included studies, most commonly employing clinical grading. Methodological quality was mixed, reflecting the predominantly retrospective, single-arm nature of the available evidence. Overall certainty of evidence was very low. Funnel plot inspection and Egger's test suggested small-study effects (p = 0.06). CONCLUSION: Lymphedema affects nearly half of patients following radiation for head and neck cancer. These findings may support routine surveillance, early identification, and timely referral for lymphedema management within survivorship care pathways. Future prospective studies should adopt standardized definitions and outcome measures to refine risk estimates and guide prevention strategies. LEVEL OF EVIDENCE: N/A.
引用
- Swisher AR, Patel E, Casaday I, et al. Radiation-Associated Lymphedema in Head and Neck Cancer: A Systematic Review and Meta-Analysis. Laryngoscope. 2026. PMID: 42838729. doi:10.1002/lary.70955
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。